Clinical Trial Update: Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating interleukin-2 plus histamine dihydrochloride in acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Histamine dihydrochloride (histamine dihydrochloride)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Maxim Pharmaceuticals | Conditions: Leukemia | Phase 3 | Status: COMPLETED